We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Incorporated (DGX - Free Report) . Apart from the United States, this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: Quest Diagnostics reported first quarter adjusted earnings of $1.52 per share (up 24.6% year-over-year) and at par with the Zacks Consensus Estimate.
Revenues: Quest Diagnostics posted revenues of $1.88 billion in the reported quarter, up 3.7% year-over-year. However, the figure missed the Zacks Consensus Estimate for revenues of $1.90 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 2.2% versus the prior year’s volume. However, revenue per requisition also increased 1.6% on a year-over-year basis.
Quest Diagnostics Incorporated Price and EPS Surprise
Major Factors: Per management, the company made great progress in accelerating growth and driving operational excellence in the reported quarter. Management has also stated that the company is a beneficiary of recent tax legislation, enabling the company to further improve earnings per share. Further, the company seems to be content with the revenue growth despite lower Medicare reimbursement under PAMA and severe winter conditions.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Quest Diagnostics (DGX) Meets Q1 Earnings, Misses Revenues (Revised)
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers– Quest Diagnostics Incorporated (DGX - Free Report) . Apart from the United States, this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: Quest Diagnostics reported first quarter adjusted earnings of $1.52 per share (up 24.6% year-over-year) and at par with the Zacks Consensus Estimate.
Revenues: Quest Diagnostics posted revenues of $1.88 billion in the reported quarter, up 3.7% year-over-year. However, the figure missed the Zacks Consensus Estimate for revenues of $1.90 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 2.2% versus the prior year’s volume. However, revenue per requisition also increased 1.6% on a year-over-year basis.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote
Major Factors: Per management, the company made great progress in accelerating growth and driving operational excellence in the reported quarter. Management has also stated that the company is a beneficiary of recent tax legislation, enabling the company to further improve earnings per share. Further, the company seems to be content with the revenue growth despite lower Medicare reimbursement under PAMA and severe winter conditions.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
(We are reissuing this article to correct a mistake. The original version, published earlier today, should no longer be relied upon.)